| http://dbpedia.org/ontology/abstract
|
The pharmaceutical industry is one of the … The pharmaceutical industry is one of the leading industries in the People's Republic of China, covering synthetic chemicals and drugs, prepared Chinese medicines, medical devices, apparatus and instruments, hygiene materials, packing materials, and pharmaceutical machinery. China has the second-largest pharmaceutical market in the world as of 2017 which is worth US$110 billion. China accounts for 20% of the world's population but only a small fraction of the global drug market. China's changing health-care environment is designed to extend basic health insurance to a larger portion of the population and give individuals greater access to products and services. Following the period of change, the pharmaceutical industry is expected to continue its expansion. China, as of 2007, has around 3,000 to 6,000 domestic pharmaceutical manufacturers and around 14,000 domestic pharmaceutical distributors. The most often-cited adverse factors in the marketplace include a lack of protection of intellectual property rights, a lack of visibility for drug approval procedures, a lack of effective governmental oversight, poor corporate support for drug research, and differences in the treatment in China that are accorded to local and foreign firms. Nevertheless, China is reportedly expected to become the third-largest pharmaceuticals market in the world by 2011. Research and development are increasing, with Shanghai becoming one of the most important global drug research centers. Most notably, Novartis is expected to establish a large Research and development base in Shanghai that will be a pillar of its drug development. China's thousands of domestic companies account for 70% of the market, the top 10 companies about 20%, according to Business China. In contrast, the top 10 companies in most developed countries control about half the market. Since 30 June 2004, the State Food and Drug Administration (SFDA) has been closing down manufacturers that do not meet the new GMP standards. Foreign players account for 10% to 20% of overall sales, depending on the types of medicines and ventures included in the count. However, sales at the top-tier Chinese companies are growing faster than at Western ones.s are growing faster than at Western ones.
, Die Pharmaindustrie in China ist eine der … Die Pharmaindustrie in China ist eine der führenden Industrien der Volksrepublik China, die 2017 mit einem Wert von insgesamt 122,6 Milliarden US-Dollar der zweitgrößte nationale Pharmamarkt der Welt war. Das Wachstum des Markts bis 2022 wird auf 145 bis 175 Milliarden US-Dollar geschätzt. Die zwei wichtigsten Aspekte des chinesischen Pharmamarkts sind zum einen das enorme Umsatzpotenzial durch die 1,3 Milliarden Einwohner des Landes, insbesondere die wachsende Mittelschicht, und zum anderen die niedrigen Lohnkosten, die Pharmaunternehmen locken Teile ihrer Produktion und Dienstleistungen an chinesische Unternehmen auszulagern.en an chinesische Unternehmen auszulagern.
, تعد الصناعة الدوائية إحدى الصناعات الرائدة … تعد الصناعة الدوائية إحدى الصناعات الرائدة في جمهورية الصين الشعبية، وتغطي المواد الكيميائية الاصطناعية والأدوية، والأدوية الصينية الجاهزة، والأجهزة الطبية، والأجهزة والأدوات، ومواد النظافة، ومواد التعبئة، وآلات صناعة المستحضرات الدوائية. تشكل الصين 20% من تعداد سكان العالم ولكن 1.5% فقط من سوق الأدوية العالمي. صُممت بيئة الرعاية الصحية المتغيرة في الصين من أجل توسيع نطاق التأمين الصحي الأساسي ليشمل شريحة أكبر من السكان وليوفر للأفراد إمكانية وصول أكبر إلى المنتجات والخدمات. بعد فترة التغيير، كان من المتوقع أن تواصل الصناعة الدوائية توسعها. يوجد بالصين، منذ عام 2007، حوالي 3000 إلى 6000 مصنع دوائي محلي وحوالي 14000 موزع دوائي محلي. من أكثر العوامل السلبية شيوعًا في السوق التجارية، الافتقار إلى حماية حقوق الملكية الفكرية، وعدم الوضوح فيما يخص إجراءات الموافقة على الأدوية، وغياب الرقابة الحكومية الفعالة، والضعف في دعم الشركات للبحوث الدوائية، والفروقات في العلاجات في الصين والتي مُنحت إلى شركات محلية وأجنبية. ومع ذلك، تفيد التقارير أنه من المتوقع أن تصبح الصين ثالث أكبر سوق للأدوية في العالم بحلول عام 2011. مع ازدياد عمليات البحث والتطوير، فقد أصبحت شنغهاي واحدة من أهم مراكز البحوث الدوائية العالمية. ومن الجدير بالذكر، أنه كان من المتوقع أن شركة نوفارتس ستنشئ قاعدة بحث وتطوير كبيرة في شنغهاي لتكون ركيزة من أجل تطوير أدويتهم. تشكل الآلاف من الشركات المحلية في الصين 70% من السوق، وتشكل أكبر عشر شركات حوالي 20%، وفقًا لبزنس شاينا. في المقابل، في معظم البلدان المتقدمة تسيطر أكبر 10 شركات على نصف السوق تقريبًا. منذ 30 يونيوعام 2004، قامت إدارة الغذاء والدواء الحكومية (إس إف دي إيه) بإغلاق الشركات المصنعة التي لا تحقق معايير جي إم بّيGMP/ الجديدة. تمثل الأطراف الفاعلة الأجنبية نسبة 10% إلى 20% من إجمالي المبيعات، اعتمادًا على أنواع الأدوية والمشاريع المدرجة في الحساب. ومع ذلك، تنمو مبيعات أهم الشركات الصينية بشكل أسرع من الشركات الغربية.ركات الصينية بشكل أسرع من الشركات الغربية.
, 中華人民共和國製藥業（英語：Pharmaceutical industry in C … 中華人民共和國製藥業（英語：Pharmaceutical industry in China）指在中華人民共和國的製藥產業，该產業涵蓋的產品包括合成化學品和藥品、中藥成藥、醫療器械、儀器和工具、衛生材料、包裝材料，及製藥機械。 中國佔世界人口的20％，但僅佔全球藥品市場銷售額的1.5％。中國醫療衛生改革不斷演進，目的在把基本醫療保險拓展到更多人口，並為個人提供更多的產品和服務。預計製藥業在這個變革時期之後，會繼續擴展。 截至2007年，中國擁有約3,000至6,000家國內藥廠，和約14,000家國內藥品經銷商。市場上最常被提及有關中國這個產業的不利因素包括：缺乏智慧財產權保護、缺乏藥物批准程序能見度、缺乏有效的政府監督、公司對藥物研發的支持不力、以及對中國國內公司和外國公司兩者的差別待遇。 尽管如此，根據報導，中國在2011年預計將成為世界第三大的藥品市場。 在中國，藥品的研究與開發在增加，上海成為最重要的全球藥品研究中心之一。最值得注意的是，總部設在瑞士的諾華藥廠有望在上海建立大型的研發基地，這個中心將成為諾華在藥物開發的重要支柱。 根據新加坡的《商業中國》報導，中國眾多的國內公司的市場佔有率是70％，排名前10名的公司約佔有市場的20％。相對的，在大多數已開發國家中，排名在前10名的公司則控制大約有一半的市場。自2004年6月30日起，中國國家食品藥品監督管理局（SFDA）開始進行關閉不符合新良好生產規範（GMP）標準的藥廠。外國藥廠佔總銷售額的10％至20％（取決於計數中所包括的藥品和企業類型）。但是中國頂級公司的銷售額增長速度快過西方公司。取決於計數中所包括的藥品和企業類型）。但是中國頂級公司的銷售額增長速度快過西方公司。
|
| http://dbpedia.org/ontology/wikiPageExternalLink
|
http://www.asia-manufacturing.com/news-227-china-apisindustry-impact-financialcrisis.html +
, http://www.accessdata.fda.gov/cms_ia/importalert_189.html +
, http://www.palgrave-journals.com/jmm/journal/v7/n1/full/5050061a.html +
, https://www.pharmaceuticalonline.com/doc/an-analysis-of-fda-warning-letters-on-data-integrity-0003 +
, http://eudragmdp.ema.europa.eu/inspections/gmpc/searchGMPNonCompliance.do +
, https://archive.today/20090514020103/http:/healthtech.who.int/tbs/ChinesePharmaceuticalPolicy/BackgroundENGdefault.htm +
, http://www.pwc.com/extweb/pwcpublications.nsf/docid/4D287C2BE1191F4A80257131004D6464 +
, http://enalteclabs.co.in +
, http://cat.inist.fr/%3FaModele=afficheN&cpsidt=1703982 +
, https://web.archive.org/web/20080622062759/http:/www.ide.go.jp/English/Publish/Asedp/075.html +
, http://www.wjcf.net/report_sample/english/848.pdf +
, http://www.genengnews.com/articles/chitem.aspx%3Faid=2049&chid=4 +
, https://web.archive.org/web/20080528052444/http:/heapol.oxfordjournals.org/cgi/reprint/20/3/185.pdf +
, http://pubs.acs.org/cen/coverstory/85/8511cover.html +
, http://pubs.acs.org/cen/coverstory/86/8605cover.html +
, https://web.archive.org/web/20080516051134/http:/www.pwc.com/extweb/pwcpublications.nsf/docid/4D287C2BE1191F4A80257131004D6464 +
, http://www.asia-manufacturing.com/news-229-pharmaceutical-financial-crisis-china-news1.html +
, https://web.archive.org/web/20090513070857/http:/www.chinalawandpractice.com/Article/1938459/Patent-System-to-Catch-Up-with-Pharmaceutical-Industry-Expansion.html +
, http://chinabioex.sites.subhub.com/ +
, http://www.ide.go.jp/English/Publish/Asedp/075.html +
, https://web.archive.org/web/20080415200357/http:/www.nrcstd.org.cn/Magazine/index.php%3FChannelID=4&NewsID=574&MagNum=2005-69&KB=1 +
, http://www.rsc.org/chemistryworld/News/2008/January/15010801.asp +
, http://www.rsc.org/chemistryworld/Issues/2007/November/ChinasDrugIndustrySetToTakeOff.asp +
, https://web.archive.org/web/20090117091821/http:/www.dfid.gov.uk/pubs/files/indiachinadomproduce.pdf +
, http://www.bioplanassociates.com/publications/articles/Biopharm_ChinaDistrib_Feb07.pdf +
, https://web.archive.org/web/20080115095226/http:/www.reuters.com/article/pressRelease/idUS123158%2B09-Jan-2008%2BBW20080109 +
, https://web.archive.org/web/20071219172911/http:/en.astrazeneca.com.cn/article/502748.aspx +
, http://www.chinadrugconsulting.com/blog/publication/overview-of-chinese-regulatory-framework/ +
, https://www.fda.gov/iceci/enforcementactions/WarningLetters/default.htm +
, https://web.archive.org/web/20071208164328/http:/chinabioex.sites.subhub.com/ +
|
| http://dbpedia.org/ontology/wikiPageID
|
2913045
|
| http://dbpedia.org/ontology/wikiPageLength
|
93457
|
| http://dbpedia.org/ontology/wikiPageRevisionID
|
1109583435
|
| http://dbpedia.org/ontology/wikiPageWikiLink
|
http://dbpedia.org/resource/Cancer_Therapeutics +
, http://dbpedia.org/resource/CapitalBio +
, http://dbpedia.org/resource/Chugai +
, http://dbpedia.org/resource/Entrepreneurship +
, http://dbpedia.org/resource/Shanghai +
, http://dbpedia.org/resource/National_Development_and_Reform_Commission +
, http://dbpedia.org/resource/Intellectual_Property_Rights +
, http://dbpedia.org/resource/Yunnan +
, http://dbpedia.org/resource/Suzhou +
, http://dbpedia.org/resource/Cheminformatics +
, http://dbpedia.org/resource/Central_planning +
, http://dbpedia.org/resource/Harbin_Pharmaceutical_Group +
, http://dbpedia.org/resource/Dosage_form +
, http://dbpedia.org/resource/Pharmaceutical_marketing +
, http://dbpedia.org/resource/E-business +
, http://dbpedia.org/resource/Sinopharm +
, http://dbpedia.org/resource/Capital_%28economics%29 +
, http://dbpedia.org/resource/China%27s_Medicine_and_Healthcare_Product_Import_and_Export_Association +
, http://dbpedia.org/resource/Bristol-Myers_Squibb +
, http://dbpedia.org/resource/China_Association_of_Pharmaceutical_Commerce +
, http://dbpedia.org/resource/C_&_O_Pharmaceutical_Technology_Holdings +
, http://dbpedia.org/resource/FeRx +
, http://dbpedia.org/resource/Chiral_Quest +
, http://dbpedia.org/resource/Chongqing_Medicine_Heping_Logistics_Center +
, http://dbpedia.org/resource/Frontage_Laboratories +
, http://dbpedia.org/resource/Pharmaceuticals +
, http://dbpedia.org/resource/Chinese_Pharmacopeia +
, http://dbpedia.org/resource/Zensun_%28Shanghai%29_Sci_&_Tech_Co.%2C_Ltd +
, http://dbpedia.org/resource/SiniWest_Holdings +
, http://dbpedia.org/resource/Shanghai_Pharmaceutical_Co. +
, http://dbpedia.org/resource/Shanghai_Schering-Plough +
, http://dbpedia.org/resource/Taisho_%28company%29 +
, http://dbpedia.org/resource/Xian-Janssen +
, http://dbpedia.org/resource/Drug_development +
, http://dbpedia.org/resource/Hoechst_Marion_Russel +
, http://dbpedia.org/resource/New_chemical_entity +
, http://dbpedia.org/resource/Paul_Appermont +
, http://dbpedia.org/resource/Technology +
, http://dbpedia.org/resource/Penicillin +
, http://dbpedia.org/resource/Sankyo_Co. +
, http://dbpedia.org/resource/Hunan +
, http://dbpedia.org/resource/Daiichi_Pharmaceutical_Co. +
, http://dbpedia.org/resource/Business-to-business +
, http://dbpedia.org/resource/Pharmacy_in_China +
, http://dbpedia.org/resource/Alliance_Boots +
, http://dbpedia.org/resource/Affymetrix +
, http://dbpedia.org/resource/Eisai +
, http://dbpedia.org/resource/State_Food_and_Drug_Administration +
, http://dbpedia.org/resource/Quality_control +
, http://dbpedia.org/resource/Hainan +
, http://dbpedia.org/resource/Biotech +
, http://dbpedia.org/resource/Drug +
, http://dbpedia.org/resource/AQSIQ +
, http://dbpedia.org/resource/Labour_%28economics%29 +
, http://dbpedia.org/resource/Pharmaceutical_industry +
, http://dbpedia.org/resource/Northern_and_southern_China +
, http://dbpedia.org/resource/East_China +
, http://dbpedia.org/resource/Public_health_in_China +
, http://dbpedia.org/resource/Medical_equipment +
, http://dbpedia.org/resource/Sinovac_Biotech +
, http://dbpedia.org/resource/Abbott_Laboratories +
, http://dbpedia.org/resource/Guangdong +
, http://dbpedia.org/resource/Rural +
, http://dbpedia.org/resource/Eli_Lilly +
, http://dbpedia.org/resource/Shenyang +
, http://dbpedia.org/resource/Heilongjiang +
, http://dbpedia.org/resource/Incentive +
, http://dbpedia.org/resource/Jiangsu +
, http://dbpedia.org/resource/Intellectual_property_rights +
, http://dbpedia.org/resource/Vaccines +
, http://dbpedia.org/resource/Novartis +
, http://dbpedia.org/resource/Orphan_drug +
, http://dbpedia.org/resource/Green_Cross_%28Japan%29 +
, http://dbpedia.org/resource/Active_pharmaceutical_ingredient +
, http://dbpedia.org/resource/Retail +
, http://dbpedia.org/resource/Pharmaceuticals_in_India +
, http://dbpedia.org/resource/Bayer +
, http://dbpedia.org/resource/Sinopharm_Group +
, http://dbpedia.org/resource/Sichuan +
, http://dbpedia.org/resource/Protein_structure_prediction +
, http://dbpedia.org/resource/Rhodia_%28company%29 +
, http://dbpedia.org/resource/Patent +
, http://dbpedia.org/resource/Natural_resource +
, http://dbpedia.org/resource/Process_optimization +
, http://dbpedia.org/resource/Health_insurance +
, http://dbpedia.org/resource/Sanofi-Aventis +
, http://dbpedia.org/resource/Medicine_in_China +
, http://dbpedia.org/resource/Clinical_trial +
, http://dbpedia.org/resource/Hubei +
, http://dbpedia.org/resource/Rational_drug_design +
, http://dbpedia.org/resource/Beijing +
, http://dbpedia.org/resource/Hebei +
, http://dbpedia.org/resource/Lonza_Group +
, http://dbpedia.org/resource/Counterfeit +
, http://dbpedia.org/resource/Joos_Horsten +
, http://dbpedia.org/resource/Takeda_Pharmaceutical_Company +
, http://dbpedia.org/resource/Boehringer_Ingelheim +
, http://dbpedia.org/resource/Manufacturing +
, http://dbpedia.org/resource/Laboratory +
, http://dbpedia.org/resource/Outsourcing +
, http://dbpedia.org/resource/Antibiotics +
, http://dbpedia.org/resource/Prostate +
, http://dbpedia.org/resource/Kyowa_Hakko +
, http://dbpedia.org/resource/Category:Pharmaceuticals_policy +
, http://dbpedia.org/resource/Hoffman-La_Roche +
, http://dbpedia.org/resource/List_of_pharmacy_schools +
, http://dbpedia.org/resource/National_pharmaceuticals_policy +
, http://dbpedia.org/resource/Janssen_Pharmaceutica +
, http://dbpedia.org/resource/Physiologically-based_pharmacokinetic_modelling +
, http://dbpedia.org/resource/Seroquel +
, http://dbpedia.org/resource/Internet +
, http://dbpedia.org/resource/Healthcare_system_reform_in_the_People%27s_Republic_of_China +
, http://dbpedia.org/resource/Investment +
, http://dbpedia.org/resource/List_of_pharmaceutical_companies +
, http://dbpedia.org/resource/Prescription_drug +
, http://dbpedia.org/resource/Roche_Applied_Science +
, http://dbpedia.org/resource/Joint_venture +
, http://dbpedia.org/resource/Dietary_supplement +
, http://dbpedia.org/resource/World_Intellectual_Property_Organization +
, http://dbpedia.org/resource/Johnson_&_Johnson +
, http://dbpedia.org/resource/Roche_Holding_AG +
, http://dbpedia.org/resource/Pain_relief +
, http://dbpedia.org/resource/Biotechnology +
, http://dbpedia.org/resource/Consumer_demand +
, http://dbpedia.org/resource/Good_manufacturing_practice +
, http://dbpedia.org/resource/Merck_&_Co. +
, http://dbpedia.org/resource/Aventis +
, http://dbpedia.org/resource/Economic_reform_in_the_People%27s_Republic_of_China +
, http://dbpedia.org/resource/Pharmaceutical_policy +
, http://dbpedia.org/resource/Fluoroquinolone +
, http://dbpedia.org/resource/Pharmacovigilance +
, http://dbpedia.org/resource/Multinational_corporation +
, http://dbpedia.org/resource/Research_and_development +
, http://dbpedia.org/resource/Japan_External_Trade_Organization +
, http://dbpedia.org/resource/Tariff +
, http://dbpedia.org/resource/Category:Pharmacy_in_China +
, http://dbpedia.org/resource/Guangzhou +
, http://dbpedia.org/resource/Merck_KGaA +
, http://dbpedia.org/resource/Schering-Plough +
, http://dbpedia.org/resource/Competition +
, http://dbpedia.org/resource/China_National_Pharmaceutical_Group +
, http://dbpedia.org/resource/Mitsubishi_Tanabe_Pharma +
, http://dbpedia.org/resource/Tianjin +
, http://dbpedia.org/resource/Ministry_of_Industry_and_Information_Technology +
, http://dbpedia.org/resource/Pharmaceutical_research +
, http://dbpedia.org/resource/State-owned +
, http://dbpedia.org/resource/Shijiazhuang +
, http://dbpedia.org/resource/Novo_Nordisk +
, http://dbpedia.org/resource/Quality_assurance +
, http://dbpedia.org/resource/Hoffmann%E2%80%93La_Roche +
, http://dbpedia.org/resource/Vertically_integrated +
, http://dbpedia.org/resource/Asia +
, http://dbpedia.org/resource/Drug_design +
, http://dbpedia.org/resource/Pharmaceutical_companies +
, http://dbpedia.org/resource/Hospital_pharmacy +
, http://dbpedia.org/resource/People%27s_Republic_of_China +
, http://dbpedia.org/resource/Butylphthalide +
, http://dbpedia.org/resource/Chongqing +
, http://dbpedia.org/resource/GlaxoSmithKline +
, http://dbpedia.org/resource/Cardiovascular +
, http://dbpedia.org/resource/Kunming_Institute_of_Botany +
, http://dbpedia.org/resource/Guizhou +
, http://dbpedia.org/resource/Guangxi +
, http://dbpedia.org/resource/Pharmacy +
, http://dbpedia.org/resource/Fujian +
, http://dbpedia.org/resource/Active_ingredient +
, http://dbpedia.org/resource/Wikt:streamline +
, http://dbpedia.org/resource/Wyeth +
, http://dbpedia.org/resource/Chinese_companies +
, http://dbpedia.org/resource/Terumo +
, http://dbpedia.org/resource/Wuxi_Pharmatech +
, http://dbpedia.org/resource/Human_resources +
, http://dbpedia.org/resource/General_Administration_of_Quality_Supervision%2C_Inspection_and_Quarantine +
, http://dbpedia.org/resource/Astellas +
, http://dbpedia.org/resource/Xi%27an +
, http://dbpedia.org/resource/IMS_Health +
, http://dbpedia.org/resource/Warburg_Pincus +
, http://dbpedia.org/resource/Science%2C_technology_and_society +
, http://dbpedia.org/resource/Patents +
, http://dbpedia.org/resource/Nexium +
, http://dbpedia.org/resource/Pfizer +
, http://dbpedia.org/resource/Product_lifecycle_%28marketing%29 +
, http://dbpedia.org/resource/Hoechst_AG +
, http://dbpedia.org/resource/Drug_discovery +
, http://dbpedia.org/resource/Dalian +
, http://dbpedia.org/resource/Tonghua +
, http://dbpedia.org/resource/Paul_Janssen +
, http://dbpedia.org/resource/China_Pharmaceutical_Industry_Association +
, http://dbpedia.org/resource/Category:Pharmaceutical_industry_in_China +
, http://dbpedia.org/resource/Wholesalers +
, http://dbpedia.org/resource/World_Trade_Organization +
, http://dbpedia.org/resource/Medicine +
, http://dbpedia.org/resource/Eli_Lilly_and_Company +
, http://dbpedia.org/resource/State_Intellectual_Property_Office +
, http://dbpedia.org/resource/Franchising +
, http://dbpedia.org/resource/Osteoporosis +
, http://dbpedia.org/resource/Shijiazhuang_Pharma_Group +
, http://dbpedia.org/resource/Central_government +
, http://dbpedia.org/resource/Degussa +
, http://dbpedia.org/resource/Reseller +
, http://dbpedia.org/resource/Hospital +
, http://dbpedia.org/resource/AstraZeneca +
, http://dbpedia.org/resource/Traditional_Chinese_medicine +
, http://dbpedia.org/resource/Therapeutics +
, http://dbpedia.org/resource/Biomedical_informatics +
, http://dbpedia.org/resource/Yamanouchi_Pharmaceutical +
, http://dbpedia.org/resource/Agreement_on_Trade-Related_Aspects_of_Intellectual_Property_Rights +
, http://dbpedia.org/resource/Dispensing_chemist +
, http://dbpedia.org/resource/Hepatitis +
, http://dbpedia.org/resource/Over-the-counter_drug +
, http://dbpedia.org/resource/Generic_drug +
, http://dbpedia.org/resource/Pharmaceutical_chemistry +
, http://dbpedia.org/resource/Category:Science_and_technology_in_the_People%27s_Republic_of_China +
, http://dbpedia.org/resource/Wuxi +
, http://dbpedia.org/resource/Bioinformatics +
, http://dbpedia.org/resource/Aspirin +
, http://dbpedia.org/resource/Zhejiang +
, http://dbpedia.org/resource/SARS +
, http://dbpedia.org/resource/Jiangsu_Yabang_Medicine_Logistics_Center +
, http://dbpedia.org/resource/Jiuzhoutong_Group_Corp. +
, http://dbpedia.org/resource/Discovery_Partners_International +
, http://dbpedia.org/resource/Jiangsu_Hengrui_Medicine_Co._Ltd. +
, http://dbpedia.org/resource/Pharmaceutics +
, http://dbpedia.org/resource/Good_Manufacturing_Practice +
, http://dbpedia.org/resource/Quanzhou_Medicine_&_Food_Logistics_Port +
, http://dbpedia.org/resource/Pharmaceutical_logistics +
|
| http://dbpedia.org/property/bot
|
BlevintronBot
|
| http://dbpedia.org/property/date
|
"2007-12-19"^^xsd:date
, "2008-05-16"^^xsd:date
, "2007-12-08"^^xsd:date
, "2008-06-22"^^xsd:date
, May 2012
|
| http://dbpedia.org/property/url
|
https://web.archive.org/web/20071219172911/http:/en.astrazeneca.com.cn/article/502748.aspx +
, https://web.archive.org/web/20071208164328/http:/chinabioex.sites.subhub.com/ +
, https://web.archive.org/web/20080516051134/http:/www.pwc.com/extweb/pwcpublications.nsf/docid/4D287C2BE1191F4A80257131004D6464 +
, https://web.archive.org/web/20080622062759/http:/www.ide.go.jp/English/Publish/Asedp/075.html +
|
| http://dbpedia.org/property/wikiPageUsesTemplate
|
http://dbpedia.org/resource/Template:Economy_of_China +
, http://dbpedia.org/resource/Template:Webarchive +
, http://dbpedia.org/resource/Template:Pharmaceutical_industry_by_country +
, http://dbpedia.org/resource/Template:Health_in_the_People%27s_Republic_of_China +
, http://dbpedia.org/resource/Template:Doi +
, http://dbpedia.org/resource/Template:Dead_link +
, http://dbpedia.org/resource/Template:Reflist +
, http://dbpedia.org/resource/Template:Clarify +
, http://dbpedia.org/resource/Template:Category_see_also +
, http://dbpedia.org/resource/Template:Use_dmy_dates +
, http://dbpedia.org/resource/Template:Pharmaceutical_companies_of_China +
, http://dbpedia.org/resource/Template:Cleanup_bare_URLs +
, http://dbpedia.org/resource/Template:Short_description +
, http://dbpedia.org/resource/Template:Citation_needed +
, http://dbpedia.org/resource/Template:Update +
, http://dbpedia.org/resource/Template:Main +
|
| http://purl.org/dc/terms/subject
|
http://dbpedia.org/resource/Category:Pharmaceuticals_policy +
, http://dbpedia.org/resource/Category:Science_and_technology_in_the_People%27s_Republic_of_China +
, http://dbpedia.org/resource/Category:Pharmacy_in_China +
, http://dbpedia.org/resource/Category:Pharmaceutical_industry_in_China +
|
| http://purl.org/linguistics/gold/hypernym
|
http://dbpedia.org/resource/Industries +
|
| http://www.w3.org/ns/prov#wasDerivedFrom
|
http://en.wikipedia.org/wiki/Pharmaceutical_industry_in_China?oldid=1109583435&ns=0 +
|
| http://xmlns.com/foaf/0.1/isPrimaryTopicOf
|
http://en.wikipedia.org/wiki/Pharmaceutical_industry_in_China +
|
| owl:sameAs |
http://www.wikidata.org/entity/Q7180753 +
, https://global.dbpedia.org/id/4tb6a +
, http://ar.dbpedia.org/resource/%D8%A7%D9%84%D8%B5%D9%86%D8%A7%D8%B9%D8%A9_%D8%A7%D9%84%D8%AF%D9%88%D8%A7%D8%A6%D9%8A%D8%A9_%D9%81%D9%8A_%D8%A7%D9%84%D8%B5%D9%8A%D9%86 +
, http://dbpedia.org/resource/Pharmaceutical_industry_in_China +
, http://de.dbpedia.org/resource/Pharmaindustrie_in_China +
, http://zh.dbpedia.org/resource/%E4%B8%AD%E5%8D%8E%E4%BA%BA%E6%B0%91%E5%85%B1%E5%92%8C%E5%9B%BD%E5%88%B6%E8%8D%AF%E4%B8%9A +
|
| rdfs:comment |
Die Pharmaindustrie in China ist eine der … Die Pharmaindustrie in China ist eine der führenden Industrien der Volksrepublik China, die 2017 mit einem Wert von insgesamt 122,6 Milliarden US-Dollar der zweitgrößte nationale Pharmamarkt der Welt war. Das Wachstum des Markts bis 2022 wird auf 145 bis 175 Milliarden US-Dollar geschätzt. Die zwei wichtigsten Aspekte des chinesischen Pharmamarkts sind zum einen das enorme Umsatzpotenzial durch die 1,3 Milliarden Einwohner des Landes, insbesondere die wachsende Mittelschicht, und zum anderen die niedrigen Lohnkosten, die Pharmaunternehmen locken Teile ihrer Produktion und Dienstleistungen an chinesische Unternehmen auszulagern.en an chinesische Unternehmen auszulagern.
, 中華人民共和國製藥業（英語：Pharmaceutical industry in C … 中華人民共和國製藥業（英語：Pharmaceutical industry in China）指在中華人民共和國的製藥產業，该產業涵蓋的產品包括合成化學品和藥品、中藥成藥、醫療器械、儀器和工具、衛生材料、包裝材料，及製藥機械。 中國佔世界人口的20％，但僅佔全球藥品市場銷售額的1.5％。中國醫療衛生改革不斷演進，目的在把基本醫療保險拓展到更多人口，並為個人提供更多的產品和服務。預計製藥業在這個變革時期之後，會繼續擴展。 截至2007年，中國擁有約3,000至6,000家國內藥廠，和約14,000家國內藥品經銷商。市場上最常被提及有關中國這個產業的不利因素包括：缺乏智慧財產權保護、缺乏藥物批准程序能見度、缺乏有效的政府監督、公司對藥物研發的支持不力、以及對中國國內公司和外國公司兩者的差別待遇。 尽管如此，根據報導，中國在2011年預計將成為世界第三大的藥品市場。 在中國，藥品的研究與開發在增加，上海成為最重要的全球藥品研究中心之一。最值得注意的是，總部設在瑞士的諾華藥廠有望在上海建立大型的研發基地，這個中心將成為諾華在藥物開發的重要支柱。瑞士的諾華藥廠有望在上海建立大型的研發基地，這個中心將成為諾華在藥物開發的重要支柱。
, The pharmaceutical industry is one of the … The pharmaceutical industry is one of the leading industries in the People's Republic of China, covering synthetic chemicals and drugs, prepared Chinese medicines, medical devices, apparatus and instruments, hygiene materials, packing materials, and pharmaceutical machinery. China has the second-largest pharmaceutical market in the world as of 2017 which is worth US$110 billion. China accounts for 20% of the world's population but only a small fraction of the global drug market. China's changing health-care environment is designed to extend basic health insurance to a larger portion of the population and give individuals greater access to products and services. Following the period of change, the pharmaceutical industry is expected to continue its expansion.try is expected to continue its expansion.
, تعد الصناعة الدوائية إحدى الصناعات الرائدة … تعد الصناعة الدوائية إحدى الصناعات الرائدة في جمهورية الصين الشعبية، وتغطي المواد الكيميائية الاصطناعية والأدوية، والأدوية الصينية الجاهزة، والأجهزة الطبية، والأجهزة والأدوات، ومواد النظافة، ومواد التعبئة، وآلات صناعة المستحضرات الدوائية. تشكل الصين 20% من تعداد سكان العالم ولكن 1.5% فقط من سوق الأدوية العالمي. صُممت بيئة الرعاية الصحية المتغيرة في الصين من أجل توسيع نطاق التأمين الصحي الأساسي ليشمل شريحة أكبر من السكان وليوفر للأفراد إمكانية وصول أكبر إلى المنتجات والخدمات. بعد فترة التغيير، كان من المتوقع أن تواصل الصناعة الدوائية توسعها. المتوقع أن تواصل الصناعة الدوائية توسعها.
|
| rdfs:label |
中华人民共和国制药业
, الصناعة الدوائية في الصين
, Pharmaindustrie in China
, Pharmaceutical industry in China
|
